Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

Only 8% of original ANDAs submitted in the user fee program’s third year were approved on the first cycle, compared with 72% that received a complete response letter.

StacksOfPapers_1200x675

More from Generics

More from Biosimilars & Generics